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Abstract
Objectives: Secondary malignancy in the oral mucosa is recognized as one of the most serious complications in
patients who received allogenic hematopoietic stem cell transplantation (HSCT). However, potential risk factors
associated with carcinogenesis after HSCT that have been reported remain elusive. We experienced a rare case of
secondary malignancies of the oral and esophageal mucosa and analyzed the expression of tumor suppressor gene
product p16.
Case report: A 35-year-old male had malignant lesions of the oral and esophageal mucosa two years after HSCT.
Partial maxillectomy and endoscopic submucosal dissection were performed. Immunohistochemical analyses
revealed that the tumor cells of malignant and premalignant lesions of the oral cavity and esophagus but not
keratosis were positive for p16.
Conclusions: Pathological examinations with p16 immunohistochemistry may contribute to an early diagnosis of
secondary malignancy after HSCT.
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Background
Allogeneic hematopoietic stem cell transplantation
(HSCT) is an increasingly therapy for hematological ma-
lignancies in recent years. Despite significant improve-
ment of survival rate, the development of secondary
malignancy has been recognized as one of the most ser-
ious long-term complications after HSCT. Malignancies
occurring after HSCT can be classified into three cat-
egories: hematological malignancy and lymphoprolifera-
tive disorder, and solid tumor [1]. Potential risk factors
associated with the development of secondary malignancy
after HSCT that have been reported include cytotoxic
effects of chemotherapeutic agents or iarradiation, chronic
graft-versus-host diseases (GVHD) related inflammation,
immunosuppression for GVHD propylaxis, viral infection
and chronic stimulation as a result of viral antigens [2,3].
Secondary solid tumor seems to be less common, but
the incidence increases significantly over time in long-
term survivors of allogenic HSCT [4]. Oral squamous
cell carcinoma (SCC) is the most common secondary
solid tumor [1,4,5]. It is considered that the presence of
chronic GVHD in oral mucosa has a significant role in
the pathogenesis of oral cancer after allogeneic HSCT
[6]. The frequent evaluations for oral chronic GVHD by
oral medicine specialists and the appropriate patho-
logical examinations with useful biomarkers may con-
tribute to an early diagnosis of oral malignancy.
The p16 protein has been identified as a tumor sup-
pressor that functions by inhibiting the cyclin-dependent
kinases 4 and 6. Overexpression of p16 protein has been
reported repeatedly in HPV-associated cancers. p16
immunohistochemistry also has been described as a
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of oral cavity [7].
Here, we report a rare case of oral and esophageal ma-
lignancy after allogeneic HSCT. An immunohistochem-
ical analysis of p16 in malignant, premalignant, and
nonmalignant lesions was performed.
Case report
Clinical history
A 35-year-old male diagnosed with malignant lymphoma
of the small intestine was treated with surgery and che-
moradiotherapy. Subsequently, he had a complete re-
sponse after autologous peripheral blood stem cell
transplantation (PBSCT). Eight years after PBSCT, he
was diagnosed with treatment-related acute myeloid
leukemia and underwent allogeneic HSCT stem cell
from a fully human leukocyte antigen–matched sibling.
He received cyclophosphamide and total body irradi-
ation for conditioning. Short-course methotrexate and
cyclosporine A (CSA) were used for GVHD prophylaxis.
A month after HSCT, he developed interstitial pneumo-
nia due to acute GVHD. He had lichenoid lesions in the
oral mucosa, keratoconjunctivitis sicca, and bronchiolitis
obliterans three months after HSCT. Oral biopsies
revealed the diagnosis chronic GVHD and showed
acanthosis of the oral epithelium. He was treated with
CSA and prednisone. Two years after HSCT, he presented
with an erosive mass in the upper gingiva and adherent
white patches in the lower gingiva (Figure 1A, B). The
diagnosis of oral SCC in the upper gingiva and low grade
dysplasia in the lower gingiva was confirmed by biopsy.Figure 1 Erosive mass in the upper gingiva (A). White patches in the lo
esophagus (C). Partial maxillectoy (D).Esophagogastroduodenoscopy (EGD) that was routinely
performed for oral malignancy patients in our hospital
revealed high grade intraepithelial neoplasia in the
esophagus (Figure 1C). The malignant and premalignant
lesions of oral cavity were surgically removed by partial
maxillectomy (Figure 1D) and CO2 laser abration. Two
month after the operation, high grade intraepithelial neo-
plasia in the esophagus was treated with endoscopic sub-
mucosal dissection (ESD). Two years after the operation,
the patient could not be followed-up in our hospital, be-
cause his lung function worsened due to chronic GVHD.
Pathological findings
Immunohistochemical staining was performed using
antibodies against p16 (Epitomics, Burlingame, USA),
p53 and Bcl-2 (Dako, Glostrup, Denmark). The proced-
ure was done according to the manufacturer’s instruc-
tions. Well-characterized samples of nonmalignant,
premalignant and malignant mucosa for immunohisto-
chemistry were selected from the biopsy specimens.
The basal and suprabasal cells’ nuclei of the acanthotic,
dysplastic and malignant lesions were positive for p53
(data not shown). The lymphocytes below the epithelium
and around SCC but not tumor cells were positive for
Bcl-2 (data not shown). The tumor cells of malignant and
premalignant lesions of the oral cavity and esophagus but
not acanthosis were positive for p16 (Figure 2).
Discussion and Conclusions
Among the late effects after HSCT, secondary solid
tumors are generally less frequent than hematologicalwer gingiva (B). Lesions unstained with lugol’s solution in the
Figure 2 Immunohistochemical analyses for the expression of p16. Acanthosis (A, B), oral epithelial dysplasia (C, D) and oral squamous cell
carcinoma (E, F) (H&E× 20) and (DAB peroxidase× 20). High grade intraepithelial neoplasia (G). The p16 positive control (lung adenocarcinoma) (H).
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time. Skin and mucosal neoplasms account for approxi-
mately one-third all secondary solid tumors in HSCT
patients, with oral squamous cell carcinoma representing
50 % of these cases [4,5,8]. However, details of the clin-
ical aspects of oral malignancies following HSCT have
been only described in several case reports [9,10]. Al-
though possible mechanisms have been previously
reported, the immunohistochemical analyses for second-
ary malignancies after GVHD are few.
GVHD is a common complication in patients who are
treated with allogeneic HSCT. It is considered that the
presence of chronic GVHD in oral mucosa has a signifi-
cant role in the pathogenesis of oral cancer afterallogeneic HSCT [2]. Lichen planus-like lesions that in-
clude hyperkeratotic striae and patches combined with
ulcerations are the most distinctive oral change of
GVHD. Differential diagnosis of oral dysplasia that may
undergo malignant transformation is sometimes difficult
in these patients.
The presence of p53 tumor suppressor gene mutations
is common molecular defects in human malignancies, in-
cluding oral SCC. p53 mutations may be related to pro-
longed exposure to immunosuppressive drugs (e.g. CSA)
[11]. However, overexpression of the mutated p53 protein,
probably related to the inflammatory infiltrate, was
detected in epithelium of oral lichen planus without dys-
plasia [12]. In our case, p53 expression was observed in
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lesions. Bcl-2 is one of the most studied anti-apoptotic
oncoprotein. Some have shown an increase in Bcl-2
expression in dysplastic and malignant lesions of the oral
cavity [13,14]. In our case, only the infiltrating lymphocytes
under the epithelium and around the tumors were positive
for Bcl-2. Therefore, p53 and Bcl-2 immunostaining is not
considered to be appropriate for the differential diagnosis of
oral dysplasia.
Although remarkable correlation between HPV detec-
tion and p16 overexpression in oropharyngeal carcinomas
has been reported, p16 overexpression was not a reliable
predictor of HPV infection in young patients with tongue
SCC [15]. One study showed that all oral SCC after HSCT
demonstrated pappillomatous aspects (a sign of HPV
infection) as well as chronic GVHD features (dense
subepithelial lymphoid infiltrate) [16]. In other report,
HPV was not associated with oral carcinogenesis after
HSCT [17]. The association of HPV infection with
esophageal intraepithelial neoplasia is also controversial.
However, it was previously reported that the only HPV-
positive cases showed strong p16 staining, compared with
HPV-negative cases in esophageal squamous intraepithe-
lial neoplasia [18]. In our case, p16 overexpression was
detected only in malignant and premalignant lesions but
not keratotic lesions. Pathological examinations with p16
immunohistochemistry may contribute to an early diagno-
sis of oral and esophageal malignancy in immunocom-
promised patients after HSCT.
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